ThinkstockAmgen Corp. (NASDAQ: AMGN) reported fiscal second quarter 2015 earnings Thursday afternoon after equity markets had closed. The biotech firm posted adjusted earnings per share (EPS) of $2.57 on revenues of $5.37…
Paul Ausick ThinkstockAmgen Inc. (NASDAQ: AMGN) is scheduled to report its earnings after the markets close on Thursday. There are consensus estimates from Thomson Reuters that call for $2.43 in earnings per share (EPS)…
Chris Lange ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or…
ThinkstockPharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc. (NYSE: MRK)…
A new research report from Cowen focuses on the top biotech stocks to buy before second-quarter earnings are reported.
24/7 Wall St. has reviewed the short interest in top biotech companies, without focusing on speculative companies.
None of these stocks are on the momentum traders' radar, and that is exactly what prudent growth investors need now.
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of July and added some color.
The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech stocks was mixed.
The May 29 short interest data have been compared with the previous figures, and for most of the selected biotech stocks, short interest has decreased.
This coming week is likely to be a serious one in the fight against cholesterol. FDA panels are evaluating more than just one drug candidate.
The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of stocks.
There were some interesting positions of hedge funds in biotech, long and short, from the Goldman Sachs Hedge Fund Trend Monitor.
The short interest data are out for the April 30 settlement date, and for most of the selected biotech stocks, short interest is down.
The short interest data are out for the April 15 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
